TORONTO, May 11, 2021 /CNW/ – Khiron Life Sciences Corp.
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, monitored by Drug Science, UK’s leading independent scientific body.
The Project Twenty 21 study has now licensed prescriptions of medical cannabis to over 900 patients who are in substantially poorer health than the general population, and who have been unable to manage their diagnosed conditions with commonly prescribed medicines.
According to the National Institute for Clinical Excellence , there is little or no evidence that commonly prescribed drugs, such as benzodiazepines or opioids, make any difference to people’s quality of life, pain or psychological distress, but they can cause harm, including possible addiction.
Our biggest contribution to improve access to medical cannabis in the UK is our education programs for prescribing clinicians and the dissemination of our expertise with cannabis-based therapeutics.
Khiron is the leading medical cannabis provider in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution and sales, and international export of both low and high THC medical cannabis products.
Leveraging wholly-owned medical clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty.
Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com.